These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2533153)

  • 1. Zoladex: therapeutic effects in postmenopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
    Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
    Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
    Robertson JF; Walker KJ; Nicholson RI; Blamey RW
    Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
    Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
    Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrinology of Zoladex in postmenopausal women.
    Dowsett M; Cantwell BM; Harris AL
    Horm Res; 1989; 32 Suppl 1():209-12. PubMed ID: 2533152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoladex in advanced breast cancer.
    Robertson JF; Nicholson RI; Walker KJ; Blamey RW
    Horm Res; 1989; 32 Suppl 1():206-8. PubMed ID: 2533151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
    Dixon AR; Robertson JF; Jackson L; Nicholson RI; Walker KJ; Blamey RW
    Br J Cancer; 1990 Nov; 62(5):868-70. PubMed ID: 2147110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
    Cassano A; Astone A; Garufi C; Noviello MR; Pietrantonio F; Barone C
    Cancer Lett; 1989 Nov; 48(2):123-4. PubMed ID: 2555044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical castration with zoladex: a conservative approach to premenopausal breast cancer.
    Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M; Bonadonna G
    Tumori; 1991 Apr; 77(2):145-50. PubMed ID: 1828640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
    Plowman PN; Nicholson RI; Walker KJ
    Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin.
    Dowsett M; Cantwell B; Lal A; Jeffcoate SL; Harris AL
    J Clin Endocrinol Metab; 1988 Apr; 66(4):672-7. PubMed ID: 2964454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of LHRH agonist, Zoladex, on ovarian histology.
    Williamson K; Robertson JF; Ellis IO; Elston CW; Nicholson RI; Blamey RW
    Br J Surg; 1988 Jun; 75(6):595-6. PubMed ID: 2969269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
    Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
    Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer.
    Nicholson RI; Walker KJ; Turkes A; Dyas J; Plowman PN; Williams M; Blamey RW
    J Steroid Biochem; 1985 Nov; 23(5B):843-7. PubMed ID: 2934580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
    Bianco AR; Rosso R; Calabresi F; Fiorentino M; Lopez M; Sismondi PG; Lenti R; Fosser V; De Placido S; Perrone F
    Eur J Gynaecol Oncol; 1991; 12(6):429-37. PubMed ID: 1839730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.